Avalyn Pharma Inc. Common Stock (AVLN) - Net Assets
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) has net assets worth $-264.25 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($135.66 Million) and total liabilities ($399.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see market cap of Avalyn Pharma Inc. Common Stock.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-264.25 Million |
| % of Total Assets | -194.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Avalyn Pharma Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Avalyn Pharma Inc. Common Stock from 2024 to 2025. See Avalyn Pharma Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-238.66 Million | -36.75% |
| 2024-12-31 | $-174.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avalyn Pharma Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8520400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.00K | % |
| Other Comprehensive Income | $134.00K | % |
| Other Components | $26.55 Million | % |
| Total Equity | $-238.66 Million | 100.00% |
Avalyn Pharma Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Avalyn Pharma Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Allied Machinery Co. Ltd.
SHG:605060
|
$1.50 Billion |
|
Tamilnad Mercantile Bank Limited
NSE:TMB
|
$1.50 Billion |
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
$1.50 Billion |
|
Yantai Zhenghai Magnetic Mat
SHE:300224
|
$1.50 Billion |
|
Henan Hanwei Electronics Co
SHE:300007
|
$1.50 Billion |
|
Fluence Energy Inc
NASDAQ:FLNC
|
$1.50 Billion |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
$1.50 Billion |
|
North Electro-Optic Co Ltd
SHG:600184
|
$1.50 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avalyn Pharma Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -174,522,000 to -238,656,000, a change of -64,134,000.
- Net loss of 85,204,000 reduced equity.
- New share issuances of 100,363,000 increased equity.
- Other comprehensive income increased equity by 134,000.
- Other factors decreased equity by 79,427,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-85.20 Million | -35.7% |
| Share Issuances | $100.36 Million | +42.05% |
| Other Comprehensive Income | $134.00K | +0.06% |
| Other Changes | $-79.43 Million | -33.28% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Avalyn Pharma Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-4.17 | $38.37 | x |
| 2025-12-31 | $-5.71 | $38.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avalyn Pharma Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.29 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.34 Million |
Industry Comparison
This section compares Avalyn Pharma Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $49,343,171
- Average return on equity (ROE) among peers: -63.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $-264.25 Million | 0.00% | N/A | $1.50 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $5.07 Billion |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more